Quotient Sciences Revenue and Competitors

UK

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Quotient Sciences's estimated annual revenue is currently $243.2M per year.(i)
  • Quotient Sciences's estimated revenue per employee is $201,000

Employee Data

  • Quotient Sciences has 1210 Employees.(i)
  • Quotient Sciences grew their employee count by 6% last year.

Quotient Sciences's People

NameTitleEmail/Phone
1
Global VP, Pharmaceutical SciencesReveal Email/Phone
2
CEOReveal Email/Phone
3
VP, Business Process IntegrationReveal Email/Phone
4
SVP & Head Candidate Development Quotient SciencesReveal Email/Phone
5
VP and General Manager, UK Early Development Site OperationsReveal Email/Phone
6
Head Bioanalytical ServicesReveal Email/Phone
7
Head Global Clincial Trial SupplyReveal Email/Phone
8
Head Bioanalytical OperationsReveal Email/Phone
9
Head Quality ControlReveal Email/Phone
10
Senior Director, Integrated Development ServicesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$86.4M4308%N/AN/A
Add Company

What Is Quotient Sciences?

Quotient Sciences is dedicated to accelerating the development of new drugs for patients around the world. We provide formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform. We employ over 700 staff and operate from state-of-the-art manufacturing and clinical facilities in the US and UK. Our people make Quotient Sciences a special place to work. We are a dedicated team passionate about innovating and transforming drug development to help our customers develop new medicines for patients in need. We recruit people that are committed to making a difference, who excel at customer service and are always willing to go the extra mile. Teamwork is integral to our culture and success — helping, supporting and mentoring run through our DNA. Expect to join an empowering and innovative culture, where we encourage continuous improvement and offer opportunities to learn and develop every day.

keywords:N/A

N/A

Total Funding

1210

Number of Employees

$243.2M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Quotient Sciences News

2022-04-06 - Clinical trials: how taking the pills may pay those bills

The Quotient Sciences trials base is just outside Nottingham, while Labcorp has a clinic in Leeds. FluCamp has facilities in London and...

2022-03-22 - Nanomerics Announces Quotient Sciences as its Clinical ...

Nanomerics Announces Quotient Sciences as its Clinical Trials Partner · LONDON, UK / ACCESSWIRE / March 28, 2022 / OC134 is enabled by...

2019-07-19 - Quotient Sciences Receives Majority Investment from Permira

Quotient Sciences, a Nottingham, England, UK-based provider of formulation development, clinical pharmacology, clinical & commercial manufacturing services to the pharmaceutical & biotech industry, received a majority stake investment from Permira. Permira Funds will acquired the stake in Quoti ...

2017-12-11 - Onespacemedia launches website to support complex rebrand of Quotient Sciences

Onespacemedia launches website to support complex rebrand of Quotient Sciences 11-12-2017 Onespacemedia has launched a new website for Quotient Sciences, to support a complex rebrand of the company. Quotient Sciences is a globally established drug development services organisation with almost ...

2017-12-11 - Onespacemedia launches website to support complex rebrand of Quotient Sciences

Onespacemedia launches website to support complex rebrand of Quotient Sciences 11-12-2017 Onespacemedia has launched a new website for Quotient Sciences, to support a complex rebrand of the company. Quotient Sciences is a globally established drug development services organisation with almost ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$340.8M121113%N/A
#2
$492.1M121210%N/A
#3
$449.7M121224%N/A
#4
$169.8M12135%N/A
#5
N/A121420%N/A